menu

CME: Precision Medicine in Advanced Prostate Cancer: A Focus on PARP Inhibitors

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Precision Medicine in Advanced Prostate Cancer: A Focus on PARP Inhibitors

close
0.50 credits
30 Minutes
Precision Medicine in Advanced Prostate Cancer: A Focus on PARP Inhibitors
Restart
Resume
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Related
Comments
  • Overview

    The management of metastatic castration-resistant prostate cancer (mCRPC) remains clinically challenging due to limited therapeutic options, treatment-associated toxicities, primary or acquired resistance to systemic hormonal therapies, limited duration of response, and the high overall mortality rate. The significance of mutations in DDR pathway genes, including BRCA1/2 and ATM, and deficits in mismatch repair have been highlighted in recent reports and further emphasized by the inclusion of recommendations for genetic counseling and testing for these alterations in the recent updates to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for prostate cancer. Emerging data from clinical studies suggest that in mCRPC inhibitors of PARP yield meaningful clinical responses and improve outcomes. Additional data pertaining to PARP inhibitors as monotherapy or in combination with other agents are anticipated to cause a paradigm shift in advanced prostate cancer management.

    The AXIS symposium exposed learners to the personal insights of several experts in the field and included in-depth analyses of the cutting-edge science on the present and future role of PARP inhibitors in prostate cancer. This web-based, on-demand activity expands the reach of the live educational activity by providing the educational content to learners who were not able to attend the live event and give them the opportunity to hear from the internationally recognized experts who presented at the live event. Key topics include evidence regarding the significance and clinical use of genetic counseling and testing, the rationale for PARP inhibitors in DDR-dysfunctional prostate cancers, and completed and ongoing clinical studies evaluating PARP inhibitors in mCRPC to enable rapid and appropriate clinical uptake of this promising class of agents. 

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Describe the significance and appropriate timing for testing for germline and somatic DNA damage repair (DDR) pathway mutations in mCRPC
    • Discuss the rationale for PARP inhibitor utilization in DDR-mutated mCRPC and the mechanism of action of this class of agents
    • Evaluate available clinical safety and efficacy data for PARP inhibitors in mCRPC
    • Incorporate strategies for identifying patients who may benefit from PARP inhibitor-based therapy
  • Target Audience

    This activity is intended for medical oncologists, urologists, pathologists, radiologists, surgical oncologists, fellows in training, and other healthcare professionals involved in the treatment of metastatic prostate cancer.

  • Disclosure of Conflicts of Interest

    Disclosure of Conflict of Interest 

    AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity.

    Name of Faculty or Presenter

    Reported Financial Relationship

    Celestia S. Higano, MD, FACP

    Celestia S. Higano, MD, FACP, reported a financial interest/relationship or affiliation in the form of Advisor: Blue Earth Diagnostics, Inc; Bayer Pharmaceuticals Corp; Clovis Oncology; Ferring Pharmaceuticals, Inc; Hinova; Janssen/Pfizer; and Janssen Oncology. Received income in any amount from: Blue Earth Diagnostics, Inc; Bayer Pharmaceuticals Corp; Clovis Oncology; Ferring Pharmaceuticals, Inc; Hinova; Janssen/Pfizer; and Janssen Oncology. Contracted research: Aragon Pharmaceuticals; Astellas Pharma US, Inc; AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Clovis Oncology; eFFECTOR Therapeutics; Emergent BioSolutions; Ferring Pharmaceuticals, Inc; Hoffmann-La Roche Inc; and Pfizer, Inc.

    Joaquin Mateo, MD, PhD

    Joaquin Mateo, MD, PhD, reported a financial interest/relationship or affiliation in the form of Serve(d) as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP and Astellas Pharma US, Inc. Research grant: AstraZeneca Pharmaceuticals LP. Consultant: AstraZeneca Pharmaceuticals LP; Janssen Oncology; Roche; and Amgen, Inc.

    Daniel P. Petrylak, MD

    Daniel P. Petrylak, MD, reported a financial interest/relationship or affiliation in the form of Consultant: Advanced Accelerator Applications; Amgen, Inc; Astellas Pharma US, Inc; AstraZeneca Pharmaceuticals LP; Bayer HealthCare, Inc; Boehringer Ingelheim; Bristol-Myers Squibb Co; Clovis Oncology; Eli Lilly and Co; Exelixis, Inc; Incyte Corp; Janssen Oncology; Pfizer, Inc; Pharmacyclics, Inc; Roche; Seattle Genetics, Inc; and Urogen. Grant/Research support: Advanced Accelerator Applications; Astellas Pharma US, Inc; AstraZeneca Pharmaceuticals LP; Bayer HealthCare, Inc; Bristol-Myers Squibb Co; Clovis Oncology; Eli Lilly and Co; Endocyte; Genentech, Inc; Innocrin; MedImmune; Merck & Co, Inc; Novartis Pharmaceuticals Corp; Pfizer, Inc; Progenics Pharmaceuticals, Inc; Roche Laboratories, Inc; sanofi-aventis; and Seattle Genetics, Inc. Ownership interest: Bellicum Pharmaceuticals, Inc and Tyme, Inc.

    The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS;  and Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

  • Accreditation and Credit Designation Statements

    ACCREDITED CONTINUING EDUCATION

    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants
    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 04/09/2021. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.5 contact hour of continuing pharmacy education credit JA4008106-0000-20-026-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

  • Provider(s)/Educational Partner(s)

    Provided by 

  • Commercial Support

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Clovis Oncology, Inc., Merck Sharp & Dohme Corp., and Pfizer Inc.

  • Terms of Use

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Method of Participation and Request for Credit:
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

    There is no fee for this educational activity.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    The management of metastatic castration-resistant prostate cancer (mCRPC) remains clinically challenging due to limited therapeutic options, treatment-associated toxicities, primary or acquired resistance to systemic hormonal therapies, limited duration of response, and the high overall mortality rate. The significance of mutations in DDR pathway genes, including BRCA1/2 and ATM, and deficits in mismatch repair have been highlighted in recent reports and further emphasized by the inclusion of recommendations for genetic counseling and testing for these alterations in the recent updates to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for prostate cancer. Emerging data from clinical studies suggest that in mCRPC inhibitors of PARP yield meaningful clinical responses and improve outcomes. Additional data pertaining to PARP inhibitors as monotherapy or in combination with other agents are anticipated to cause a paradigm shift in advanced prostate cancer management.

    The AXIS symposium exposed learners to the personal insights of several experts in the field and included in-depth analyses of the cutting-edge science on the present and future role of PARP inhibitors in prostate cancer. This web-based, on-demand activity expands the reach of the live educational activity by providing the educational content to learners who were not able to attend the live event and give them the opportunity to hear from the internationally recognized experts who presented at the live event. Key topics include evidence regarding the significance and clinical use of genetic counseling and testing, the rationale for PARP inhibitors in DDR-dysfunctional prostate cancers, and completed and ongoing clinical studies evaluating PARP inhibitors in mCRPC to enable rapid and appropriate clinical uptake of this promising class of agents. 

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Describe the significance and appropriate timing for testing for germline and somatic DNA damage repair (DDR) pathway mutations in mCRPC
    • Discuss the rationale for PARP inhibitor utilization in DDR-mutated mCRPC and the mechanism of action of this class of agents
    • Evaluate available clinical safety and efficacy data for PARP inhibitors in mCRPC
    • Incorporate strategies for identifying patients who may benefit from PARP inhibitor-based therapy
  • Target Audience

    This activity is intended for medical oncologists, urologists, pathologists, radiologists, surgical oncologists, fellows in training, and other healthcare professionals involved in the treatment of metastatic prostate cancer.

  • Disclosure of Conflicts of Interest

    Disclosure of Conflict of Interest 

    AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity.

    Name of Faculty or Presenter

    Reported Financial Relationship

    Celestia S. Higano, MD, FACP

    Celestia S. Higano, MD, FACP, reported a financial interest/relationship or affiliation in the form of Advisor: Blue Earth Diagnostics, Inc; Bayer Pharmaceuticals Corp; Clovis Oncology; Ferring Pharmaceuticals, Inc; Hinova; Janssen/Pfizer; and Janssen Oncology. Received income in any amount from: Blue Earth Diagnostics, Inc; Bayer Pharmaceuticals Corp; Clovis Oncology; Ferring Pharmaceuticals, Inc; Hinova; Janssen/Pfizer; and Janssen Oncology. Contracted research: Aragon Pharmaceuticals; Astellas Pharma US, Inc; AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Clovis Oncology; eFFECTOR Therapeutics; Emergent BioSolutions; Ferring Pharmaceuticals, Inc; Hoffmann-La Roche Inc; and Pfizer, Inc.

    Joaquin Mateo, MD, PhD

    Joaquin Mateo, MD, PhD, reported a financial interest/relationship or affiliation in the form of Serve(d) as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP and Astellas Pharma US, Inc. Research grant: AstraZeneca Pharmaceuticals LP. Consultant: AstraZeneca Pharmaceuticals LP; Janssen Oncology; Roche; and Amgen, Inc.

    Daniel P. Petrylak, MD

    Daniel P. Petrylak, MD, reported a financial interest/relationship or affiliation in the form of Consultant: Advanced Accelerator Applications; Amgen, Inc; Astellas Pharma US, Inc; AstraZeneca Pharmaceuticals LP; Bayer HealthCare, Inc; Boehringer Ingelheim; Bristol-Myers Squibb Co; Clovis Oncology; Eli Lilly and Co; Exelixis, Inc; Incyte Corp; Janssen Oncology; Pfizer, Inc; Pharmacyclics, Inc; Roche; Seattle Genetics, Inc; and Urogen. Grant/Research support: Advanced Accelerator Applications; Astellas Pharma US, Inc; AstraZeneca Pharmaceuticals LP; Bayer HealthCare, Inc; Bristol-Myers Squibb Co; Clovis Oncology; Eli Lilly and Co; Endocyte; Genentech, Inc; Innocrin; MedImmune; Merck & Co, Inc; Novartis Pharmaceuticals Corp; Pfizer, Inc; Progenics Pharmaceuticals, Inc; Roche Laboratories, Inc; sanofi-aventis; and Seattle Genetics, Inc. Ownership interest: Bellicum Pharmaceuticals, Inc and Tyme, Inc.

    The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS;  and Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

  • Accreditation and Credit Designation Statements

    ACCREDITED CONTINUING EDUCATION

    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants
    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 04/09/2021. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.5 contact hour of continuing pharmacy education credit JA4008106-0000-20-026-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

  • Provider(s)/Educational Partner(s)

    Provided by 

  • Commercial Support

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Clovis Oncology, Inc., Merck Sharp & Dohme Corp., and Pfizer Inc.

  • Terms of Use

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Method of Participation and Request for Credit:
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

    There is no fee for this educational activity.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 8/4/20